Medicare AdvantageCoverageMedium impact
MA08.083l, Leuprolide (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)
Independence Blue Cross·Oncology, Endocrinology, Urology +1 more·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.083l has been updated with changes to medical necessity criteria and general guidelines for Leuprolide products (Camcevi, Eligard, Fensolvi, Lupron Depot). This affects coverage requirements for hormone therapy medications used primarily in oncology and endocrinology.
Action Required
By December 29, 2025: Billing team must review updated medical necessity criteria for Leuprolide products (Camcevi, Eligard, Fensolvi, Lupron Depot) in Medicare Advantage plans. Access full policy details at the provided URL to understand new documentation requirements. Update prior authorization workflows and provider templates accordingly to ensure compliance with revised guidelines.